Reviews in Endocrine and Metabolic Disorders

, Volume 2, Issue 4, pp 403–418

Drug Treatment of Obesity

  • George A. Bray
sibutramine orlistat ephedrine thermogenic monoamine peptides leptin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bray GA, Greenway FL. Current and potential drugs for treatment of obesity [Review]. Endocr Rev 1999;20:805-875.Google Scholar
  2. 2.
    Weintraub M, Bray GA. Drug treatment of obesity [Review]. Med Clin North Am 1989;73:237-249.Google Scholar
  3. 3.
    Bray GA. Obesity--A time-bomb to be defused. Lancet 1998;352:160-161.Google Scholar
  4. 4.
    Ryan DH, Bray GA, Helmcke F et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes Res 1999;7:313-322.Google Scholar
  5. 5.
    McMahon FG, Fujioka K, Singh BN, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. Efficacy and safety of sibutramine in obese white and African-American patients with hypertension. Arch Int Med 2000;160:2185-2191.Google Scholar
  6. 6.
    Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306-313.Google Scholar
  7. 7.
    Flechtner-Mors M, Ditschuneit HH, Johnson TD, Suchard MA, Adler G. Metabolic and weight loss effects of long-term dietary intervention in obese patients: Four-year results. Obes Res 2000;8:399-402.Google Scholar
  8. 8.
    Munro JF, MacCuish AC, Wilson EM et al. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968;1:352-354.Google Scholar
  9. 9.
    Greenway FL, Ryan DH, Bray GA, Rood JC, Tucker EW, Smith SR. Pharmaceutical cost savings of treating obesity with weight loss medications. Obes Res 1999;7:523-531.Google Scholar
  10. 10.
    Astrup A, Breum L, Tourbro S et al. The effect and satiety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placeo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes 1992;16:260-277.Google Scholar
  11. 11.
    Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999;7:477-484.Google Scholar
  12. 12.
    Foster GD, Wadden TA, Vogt RA et al. What is a reasonable weight loss? Patients expectations and evaluations of obesity treatment outcomes. J Consult Clin Psychol 1997;65:79-85.Google Scholar
  13. 13.
    Bray GA. Evaluation of drugs for treating obesity [Review]. Obes Res 1995;3Suppl 4:425S-434S.Google Scholar
  14. 14.
    Bray GA, Tartaglia LA. Medicinal strategies in the treatment of obesity [Review]. Nature 2000;404(6778):672-677.Google Scholar
  15. 15.
    National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity [Review]. JAMA 1996;276:1907-1915.Google Scholar
  16. 16.
    Scoville B. Review of amphetamine-like drugs by the Food and Drug Administration: Clinical data and value judgments. In: Obesity in Perspective. Washington: Department of Health, Education, and Welfare, Publication no. 75-708, 1975:441-443.Google Scholar
  17. 17.
    Silverstone JJ, Solomon T. The long-term management of obesity in general practice. Br J Clin Pract 1965;19:395-398.Google Scholar
  18. 18.
    McKay RHG. Long-term use of diethylpropion in obesity. Curr Med Res Opin 1973;1:489-493.Google Scholar
  19. 19.
    Langlois KJ, Forbes JA, Bell GW, Grant GF Jr. A double-blind clinical evaluation of the safety and efficacy of phentermine hydrochloride (Fastin) in the treatment of exogenous obesity. Curr Ther Res 1974;16:289-296.Google Scholar
  20. 20.
    Gershberg H, Kane R, Hulse M, Pensgen E. Effects of diet and an anorectic drug (phentermine resin) in obese diabetics. Curr Ther Res 1977;22:814-820.Google Scholar
  21. 21.
    Campbell CJ, Bhalla IP, Steel JM, Duncan LJP. A controlled trial of phentermine in obese diabetic patients. Practitioner 1977;218:851-855.Google Scholar
  22. 22.
    Williams RA, Foulsham BM. Weight reduction in osteoarthritis using phentermine. Practitioner 1981;225:231-232.Google Scholar
  23. 23.
    Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: A dose-ranging, efficacy study. Clin Pharmacol Ther 1991;50:330-337.Google Scholar
  24. 24.
    Jones SP, Smith IG, Kelly F, Gray JA. Long-term weight loss with sibutramine. Int J Obes 1995;19(Suppl 2):40.Google Scholar
  25. 25.
    Bray GA, Ryan DH, Gordon D, Heidingsfelder S, Cerise F, Wilson K. 1996 A double-blind randomized placebo-controlled trial of sibutramine. Obes Res 1996;4:263-270.Google Scholar
  26. 26.
    Hanotin C, Thomas F, Jones SP, Leutenegger E, Drouin P. Efficacy and tolerability of sibutramine in obese patients: A dose-ranging study. Int J Obes Relat Metab Disord 1998;22:32-58.Google Scholar
  27. 27.
    Bray GA, Blackburn GL, Ferguson JM, Greenway FL, Jain AK, Mendel CM, Mendels CM, Mendels J, Ryan D, Schwartz SL, Scheinbaum ML, Seaton TB. Sibutramine produces dose-related weight loss. Obes Res 1999;7:189-198.Google Scholar
  28. 28.
    Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-184.Google Scholar
  29. 29.
    Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes 2000;24:144-150.Google Scholar
  30. 30.
    James WPT, Astrup A, Finer N, Hilsted J, Kopelman P, Rossner S, Saris WHM, van Gaal L, for the STORM study group. Effect of sibutramine on weight maintenance after weight loss: A randomized trial. Lancet 2000;356:2119-2125.Google Scholar
  31. 31.
    Sramek, JJ, Seiowitz MT, Weinstein SP, Rowe ED, Mendel CM, Levy B, McMahon FG, Mullican WS, Toth PD, Cutler NR. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: A placebo-controlled, double-blind, randomized trial. Am J Hypertension 2001 [in press].Google Scholar
  32. 32.
    Finer N, Bloom SR, Frost GS, Banks LM, Griffiths J. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: A randomised, double-blind placebo-controlled study. Diab Obes Metab 2000;2:105-112.Google Scholar
  33. 33.
    Fujioka K, Seaton TB, Rowe E, Jelinek CA, RaskinP, Lebovitz HE, Weinstein SP, and the Sibutramine/Diabetes clinical study group. Weight loss with sibutramine improves glycemic control and other metabolic parameters in obese type 2 diabetes mellitus. Diab Obes Metab 2000;2:1-13.Google Scholar
  34. 34.
    Wadden RA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R, Steinberg CM. Benefits of lifestyle modification in the pharmacologic treatment of obesity: A randomized trial. Arch Intern Med 2001;161:218-227.Google Scholar
  35. 35.
    Kernan WN, Viscoli CM, Brass LM, Broderick JP, Brott T, Feldmann E, Morgenstern LB, Wilterdink JL, Horwitz RI. Phenylpropanolamine and the risk of hemorrhagic stroke. N Engl J Med 2000;343(25):1826-1832.Google Scholar
  36. 36.
    Weintraub M. Long term weight control: The National Heart, Lung, and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992;51:581-585.Google Scholar
  37. 37.
    Connolly HM, Crary JL, McGoon MD et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:581-588.Google Scholar
  38. 38.
    Mast ST, Jollis JG, Ryan T, Anstrom KJ, Crary JL. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Ann Intern Med 2001;134:261-266.Google Scholar
  39. 39.
    Greenway FL. Buproprion SR significantly enhances weight loss when used with a moderate-intensity lifestyle intervention [Abstract]. Diabetes 2001 (in press).Google Scholar
  40. 40.
    Rosenfeld WE, Kanner A, Jacobson N, Kretschner P, and the PADS Investigator Group. Topiramate and concomitant weight loss. Epilepsia 1997;38(Suppl 8):98.Google Scholar
  41. 41.
    Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O'Rahilly S. Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903-908.Google Scholar
  42. 42.
    Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes IA, McCamish MA, O'Rahilly S. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N Engl J Med 1999;341:879-884.Google Scholar
  43. 43.
    Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, Patane J, Self B, Hunt P, McCamish M. Recombinant leptin for weight loss in obese and lean adults: A randomized, controlled, dose-escalation trial. JAMA 1999;282:1568-1575.Google Scholar
  44. 44.
    Huckshorn CJ, Saris WH, Westerterp-Plantenga et al. Weekly subcutaneous pegylated recombinant native human leptin (PEGOB) administration in obese men. J Clin Endocrinol Metab 2000;85:4003-4009.Google Scholar
  45. 45.
    Lambert PD, Anderson KD, Sleeman MW, Wong V, Tan J, Hijarunguru A, Corcoran TL, Murray JD, Thabet KE, Yancopoulos GD, Wiegand SJ. Ciliary neurotrophic factor activates leptin-like pathways and reduces body fat, without cachexia or rebound weight gain, even in leptin-resistant obesity. Proc Nat Acad Sci 2001;98:4652-4657.Google Scholar
  46. 46.
    Guler HP, Ettinger TW, Littlejohn SL, Schwartz SL, Weiss SL, McIlwain HH, Heymsfield SB, Bray GA, Roberts WG, Acheson A, Heyman ER, Dark CL, Vicary C. Axokine causes significant weight loss in severely and morbidly obese subjects. Int J Obes 2001 (in press).Google Scholar
  47. 47.
    Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998;101:515-520.Google Scholar
  48. 48.
    Al-Barazanji KA, Arch JR, Buckingham RE, Tadayyon M. Central exendin-4 infusion reduces body weight without altering plasma leptin in (fa/fa) Zucker rats. Obes Res 2000;8:317-323.Google Scholar
  49. 49.
    Schwartz MW, Woods SC, Porte D, Seeley RJ, Baskin DG. Central nervous system control of food intake [Review]. Nature. 2000;404(6778):661-671.Google Scholar
  50. 50.
    Bruning JC, Gautam D, Burks DJ, Gillette J, Schubert M, Orban PC, Klein R, Krone W, Muller-Wieland D, Kahn CR. Role of brain insulin receptor in control of body weight and reproduction. Science 2000;289(5487):2122-2125.Google Scholar
  51. 51.
    Lustig RH, Rose SR, Burghen GA, Velasquez-Mieyer P, Broome DC, Smith K, Li H, Hudson MM, Heideman RL, Kun LE. Hypothalamic obesity caused by cranial insult in children: Altered glucose and insulin dynamics and reversal by a somatostatin agonist. J Pediatr 1999;135(2 Pt 1):162-168.Google Scholar
  52. 52.
    Hauptmann JB, Jeunet FS, Hartmann D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro18-0647 (tetrahydrolipstatin). Am J Clin Nutr 1992;5:309S-313S.Google Scholar
  53. 53.
    Drent ML, Larsson I, William-Olsson T, Quadde F, Czubayko F, von Bergmann K, Strobel W, Sjostrom L, van der Veen EA. Orlistat (Ro18-0647), a lipase inhibitor, in the treatment of human obesity: A multiple dose study. Int J Obes 1995;19:221-226.Google Scholar
  54. 54.
    James WPT, Avenell A, Broom J, Whitehead J. A one-year trial to assess the value of orlistat in the management of obesity. 1997;21(3):S24-S30.Google Scholar
  55. 55.
    Van Gaal LF, Broom JI, Enzi G, Toplak H. Efficacy and tolerability of orlistat in the treatment of obesity--A 6-month dose-ranging study. Eur J Clin Pharm 1998;54:125-132.Google Scholar
  56. 56.
    Sjostrom L, Rissanen A, Andersen T et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352:167-172.Google Scholar
  57. 57.
    Davidson MH, Hauptman J, DiGirolamo M, Foreyt JP, Halsted CH, Heber D, Heimburger DC, Lucas CP, Robbins DC, Chung J, Heymsfield SB. Long-term weight control and risk factor reduction in obese subjects treated with orlistat, a lipase inhibitor. JAMA 1999;281:235-242.Google Scholar
  58. 58.
    Finer N, James WP, Kopelman PG, Lean ME, Williams G. One-year treatment of obesity: A randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000;24:306-313.Google Scholar
  59. 59.
    Rossner S, Sjostrom L, Noack R, Meinders AE, Noseda G, on behalf of the European Orlistat Obesity Study Group. Weight loss, weight maintenance, and improved cardiovascular riskfactors after 2 years treatment with orlistat for obesity. Obes Res 2000;8:49-61.Google Scholar
  60. 60.
    Hauptmann J, Lucas C, Boldrin MN, Collins H, Segal KR, for the Orlistat Primary Care Study Group. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-167.Google Scholar
  61. 61.
    Lindgarde F, on behalf of the Orlistat Swedish Multimorbidity study group. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity study. J Intern Med 2000;248:245-254.Google Scholar
  62. 62.
    Hill JO, Hauptmann, J, Anderson JW, Fujioka K, O'Neil PM, Smith DK, Zavoral JH, Aronne LJ. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: A 1-y study. Am J Clin Nutr 1999;69:1108-1116.Google Scholar
  63. 63.
    Drent ML, van der Veen EA. First clinical studies with orlistat: A short review. Obes Res 1995;3:S623-S625.Google Scholar
  64. 64.
    Hollander P, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J. Role of Orlistat in the treatment of obese patients with type 2 diabetes. Diab Care 1998;21:1288-1294.Google Scholar
  65. 65.
    Heymsfield, SB, Segal KR, Hauptman, J, Lucas CP, Boldrin MN, Rissanen A, JPH Wilding Sjostrom L. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 Diabetes in obese adults. Arch Intern Med 2000;160:1321-1326.Google Scholar
  66. 66.
    Reaven G, Segal K, Haputman J, Boldrin M, Lucas C. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with Syndrome X. Am J Med 2001 [in press].Google Scholar
  67. 67.
    Tonstad S, Pometta D, Erkelens DW, Ose L, Moccetti T, Schouten JA, Golay A, Reitsma J, Del Bufalo A, Pasotti E. The effects of gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994;46:405-410.Google Scholar
  68. 68.
    Mittendorfer B, Ostlund R, Patterson BW, Klein S. Orlistat inhibits dietary cholesterol absorption. Obes Res 2000;8(Suppl 1):43S.Google Scholar
  69. 69.
    Wadden TA, Berkowitz RI, Womble LG, Sarwer DB, Arnold ME, Steinberg CM. Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: A placebo-controlled trial. Obes Res 2000;8(6):431-437.Google Scholar
  70. 70.
    Astrup A, Bulow J, Madsen J, Christensen NJ. Contribution of BAT and skeletal muscle to thermogenesis induced by ephedrine in man. Am J Physiol. 1985;248(5 Pt 1):E507-E515.Google Scholar
  71. 71.
    Astrup A, Breum L, Toubro S. Pharmacological and clinical studies of ephedrine and other thermogenic agonists [Review]. Obes Res 1995;3Suppl 4:537S-540S.Google Scholar
  72. 72.
    Larsen TM, Toubro S, van Baak MA, Gottesdiener KM, Larson P, Saris WHM, Astrup A. No thermogenic effect after 28 days treatment with L-796,568, a novel beta-3-adrenoceptor, in obese men. Obes Res 2000;8(Suppl 1):44S.Google Scholar
  73. 73.
    Heymsfield SB, Allison DB, Vasselli JR, Pietrobelli A, Greenfield D, Nunez C. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: A randomized controlled trial. JAMA 1998;280:1596-1600.Google Scholar
  74. 74.
    Guerciolini R, Radu-Radulescu L, Boldrin M, Moore R. Fecal fat excretion induced by treatment with orlistat or chitosan: A 3-week randomized crossover design study. Obes Res 2000;8(Suppl 1):43S.Google Scholar
  75. 75.
    Pittler MH, Abbot NC, Harkness EF, Ernst E. Randomized, double-blind trial of chitosan for body weight reduction. Eur J Clin Nutr 1999;53(5):379-381.Google Scholar
  76. 76.
    Nasser JA et al. 1999. Efficacy trial for weight loss of an herbal supplement of Ma Huang and guarana. FASEB J 1999;13(5).Google Scholar
  77. 77.
    Boozer CN, Daly PA, Blanchard D, Nasser JA, Solomon JL, Homel P. Herbal ephedra/caffeine for weight loss: A 6-month safety and efficacy trial [Abstract]. Obes Res 2001;9(1):68.Google Scholar

Copyright information

© Kluwer Academic Publishers 2001

Authors and Affiliations

  • George A. Bray
    • 1
  1. 1.Pennington Biomedical Research CenterLouisiana State UniversityBaton Rouge

Personalised recommendations